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Abstract
Spherical MCM-41 silica nanosized particles were synthesized and post synthesis modified by 
3-aminopropyltriethoxysilane (APTES) in order to prepare amino-functionalized carrier. Both 
types of silica particleswere loaded with indometacin and further coated with carbopol. The 
preservation of morphology and pore structure of the particles was observed by XRD, TEM and 
N2 physisorption.  FT-IR  spectroscopy revealed  the  interaction  between  carboxyl  groups  of 
indometacin and the amino groups of the functionalized MCM-41. Amino-functionalization of 
the carrier resulted in higher degree of indometacin loading in comparison to the parent MCM-
41, 39% vs. 30%, respectively. The coating of drug loaded amino-MCM-41 silica particles with 
carbopol  significantly  reduced  the  initial  burst  release  of  indometacin.  Both  silica  carriers 
demonstrated no cytotoxicity on HL-60 (acute myeloid leukemia) and K-562 (chronic myeloid 
leukemia) cell lines.
1. Introduction
Mesoporous silica materials are in focus of research due to their porous structure and high 
surface area. Recently, research has been focused on the application of mesoporous silica based 
materials as a potential drug delivery system  [1–5]. Their excellent biocompatibility and the 
capability to be functionalized with different organic groups make them attractive candidates 
for a wide range of biomedical purposes, such as controlled drug delivery [6,7]. The most often 
used mesoporous silica based drug carrier has been the ordered hexagonal MCM-41 molecular 
sieve. The appropriate chemical modification of the surface of the mesoporous matrix could 
enhance the adsorption of drug molecules [3,8]. Modification of MCM-41 by different organic 
groups  (amino,  carboxyl,  chloropropyl,  phenyl,  benzyl,  mercaptopropyl,  cyanopropyl,  butyl 
groups etc.)  improved the drug loading due to the eventual interactions with the functional 
groups of the drug. Further, the formation of bonds could overcome the problems associated 
with the burst release of the incorporated drug molecule [3]. Doadrio et al. have reported that 
erythromycin release from functionalized matrices was much slower compared to unmodified 
material [9]. Basaldella and Legnoverde have reported that the initial release of cephalexin was 
not influenced by functionalization of SBA-15 carrier but the second stage of the release was 
significantly  influenced  [10].  On  the  other  hand,  the  undesired  burst  release  of  the  drug 
molecule incorporated into mesoporous particles could be avoided by coating or capping the 
pores of the particles. In the recent years drug release has been controlled by closing the pore 
entrances with CdS, gold nanoparticle caps, or silica nanoparticles were covered by pH and 
temperature sensitive coatings  [11–18]. For instance, capping the pores by CdS nanoparticles 
via a chemically cleavable disulfide link hindered the initial release of the entrapped drug [11]. 
Poly(acrylic acid) and poly(methacrylic acid) were grafted on the surface of mesoporous silica 
particles in order to provide pH-controlled drug release [16,17]. You et al.  [18] have reported 
temperature-controlled  release  systems  applying  a  temperature-responsive  polymer.  Coating 
with bioadhesive polymers could be considered as a new direction of research that is still in the  
initial  stage.  In  our  opinion,  formation  of  a  bioadhesive  polymer  coating  layer  around 
nanoparticles could hinder the rapid burst release of the loaded drug as well as to promote the  
interactions  between gastrointestinal  mucosa  and nanoparticles.  The latter  is  closely related 
with a prolongation of gastrointestinal residence of the drug-loaded particles and an eventual 
subsequent improvement of oral bioavailability, especially for poorly soluble drugs.
Indometacin  is  an  acidic  non-steroidal  anti-inflammatory  drug  causing  irritation  of  the 
gastrointestinal mucosa  [19]. The side effects have been considered as combination of local 
irritation due to the direct contact of free carboxyl group of indometacin and local inhibition of 
cytoprotective  action  of  prostaglandins  on  gastric  mucosa  [20].  Some  researchers  have 
developed  indometacin  prodrugs  that  reduced  the  occurrence  of  the  side  effects  due  to 
esterification  of  the  carboxyl  groups  of  indometacin  and  their  slow  hydrolysis  in 
gastrointestinal  tract  [21].  However,  the  development  of  the  pro-drugs  requires  optimal 
protection of the drug until it reaches the desired site to by hydrolyzed.
The aim of the present study was to prevent the initial contact between indometacin and 
gastrointestinal mucosa by its incorporation into the pores of the mesoporous silica particles. 
Aminofunctionalized MCM-41NH2 carrier was prepared aiming to bind the carboxyl group of 
indometacin and to improve drug loading degree. The concept of silica functionalization was 
combined with the post-coating of the mesoporous particles with a polymer in order to avoid 
burst release of the loaded drug. Carbopol was selected as coating polymer taking into account 
the eventual electrostatic interaction between its carboxylic groups and amino groups located on 
the  surface  of  the  functionalized  carrier.  In  addition,  the  coating  of  mesoporous  silica 
nanoparticles  with  carbopol  could  promote  bioadhesive  interactions  between  the  modified 
particles  and  the  cells  of  gastrointestinal  mucosa  being  a  very  important  factor  for  drug 
bioavailability.
2. Experimental
2.1. Synthesis of MCM-41 spherical silica materials
Spherical nanosized MCM-41 particles were prepared according to the procedure of Huh et 
al.  [22].  This  sol–gel  procedure  is  carried  out  at  353 K without  co-solvent,  only in  water 
solution and with NaOH as a catalyst. The relative molar composition of the reaction mixture 
was: 
1 TEOS: 0.12 C16TMABr: 0.31 NaOH: 1190 H2O. 
The formed gel was aged at 353 K for 2 h, than washed with distilled water until neutral pH, 
and dried at ambient. Template removal of MCM-41 materials was carried out in air at 823 K 
with 1 K/min rate for 5 h.
2.2. Modification of the materials by APTES
Modification of the spherical MCM-41 material with amino groups was accomplished by 
reaction with 3-aminopropyltriethoxysilane (APTES) in toluene (333 K, 24 h). Following the 
reaction samples were washed with several portions of toluene, methanol and finally water. 20 
ml APTES in 100 ml toluene was applied to 1 g of silica. The APTES modified samples were  
designated as MCM-41NH2.
2.3. Indometacin loading and carbopol coating of parent MCM-41 and amino-functionalized 
MCM-41NH2 samples
Indometacin  and  powdered  mesoporous  samples  were  incubated  into  ethanol  under 
continuous magnetic  stirring for  24 h at  310 K.  In particular,  100 mg of indometacin was 
dissolved in 10 ml of ethanol and 100 mg of dried mesoporous silica was put into this solution. 
After incubation for 24 h,  the mixture was centrifuged at  15,000 rpm, rinsed with purified 
water,  separated  by  a  second  centrifugation,  and  finely  dried  at  room  temperature  under 
vacuum. The samples were abbreviated as MCM-41IND and MCM-41NH2IND, respectively. 
Drug  loaded  MCM-41IND  or  amino-functionalized  MCM-41NH2IND  particles  were 
incubated in an queous phase containing carbopol (0.012% wt.) under gentle stirring (100 rpm) 
for 2 h. After incubation, the dispersions were centrifuged at 15,000 rpm for 15 min, rinsed with 
distilled water, separated by a second centrifugation, and finely dried at room temperature under 
vacuum.  The  amount  of  indometacin  in  the  supernatants  was  measured  by  UV-
spectrophotometry at  a wavelength of 320 nm (Hewlet Packard 8452A). The samples were 
abreviated as MCM-41INDC and MCM-41NH2INDC, respectively.
2.4. Characterization of the samples
X-ray diffractograms were recorded by a Philips PW 1810/3710 diffractometer with Bregg–
Brentano parafocusing geometry applying monochromatized Cu Ka (λ = 0.15418 nm) radiation 
(40 kV, 35 mA) and a proportional counter.
Nitrogen physisorption measurements were carried out at 77 K using Quantachrome NOVA 
Automated  Gas  Sorption  Instrument.  The  pore-size  distribution  was  calculated  from  the 
desorption branch of the isotherms with the BJH method. Pure silica samples were pre-treated 
at  623  K,  whereas  amino  modified  and  drug  loaded  materials  at  353  K  for  5  h  before 
measurements.
Attenuated Total Reflection Infrared (ATR–FTIR) spectra were recorded by means of a Varian 
Scimitar 2000 FTIR spectrometer equipped with a MCT (mercury–cadmium–tellur) detector 
and a single reflection ATR unit (SPECAC ‘‘Golden Gate’’) with diamond ATR element. In 
general,  128 scans  and 4 cm-1 resolution  were applied.  For  all  spectra  ATR-correction  was 
performed (Varian ResPro 4.0 software).
NMR spectra were recorded on a Bruker Avance II +600 NMR spectrometer operating at 
600.13 MHz proton frequency (150.90 MHz for 13C), using 4 mm solid state CP/MAS dual 
probe head. The samples were loaded in 4 mm zirconia rotors and spun at magic angle spinning 
(MAS) rate of 6 kHz in all experiments. 13C NMR spectra were acquired with 8 K time domain 
data points, spectrum width of 50 kHz, 256 scans and a recycle delay of 5 s, using a cross  
polarization pulse sequence with total suppression of side bands (cptoss) from Bruker Topspin 
library.  The spectra  were  processed  with  an exponential  window function  (line  broadening 
factor 10) and zero filled to 16 K data points.
TEM images were taken by using a MORGAGNI 268D TEM (100 kV; W filament; point-
resolution = 0.5 nm).
The thermogravimetric measurements were performed with a Setaram TG92 instrument with 
a heating rate of 5 K/min in nitrogen flow.
Determination of nanoparticle size was performed using a Zetasizer (Zetasizer Nano ZS, 
Malvern Instruments, Worcestershire, UK). The samples were dispersed in distilled water and 
measuredat scattering angles of 90° at 298 K.
2.5. In vitro release studies
For in vitro release studies, 10 mg of the drug loaded silica particles were incubated in 200 
ml simulated gastric (pH = 1.2) or simulated intestinal fluid (pH = 6.8) at 310 K under stirring  
(100 rpm). At appropriate time intervals, 5 ml samples were withdrawn and replaced by fresh 
buffer.  The  withdrawn  samples  were  centrifuged  at  15,000  rpm  for  15  min  and  the 
concentration  of  the  released  indomethacin  into  the  supernatant  was  determined  by  UV-
spectrophotometry at a wavelength of 320 nm (Hewllet Packard 8452A).
2.6. In vitro cytotoxicity assay
The cell lines HL-60 (acute myeloid leukemia) and K-562 (chronic myeloid leukemia) were 
purchased from the German Collection of Microorganism and Cell Cultures (DSMZ), Germany. 
Both cell lines were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated 
fetal calf serum and L-glutamine. They were incubated in a controlled environment (310 K, 5% 
carbon dioxide humidified atmosphere). 
The cellular viability was chosen as a cytotoxicity end-point and determined using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  (MTT)  dye  reduction  assay.  The 
MTT assay was applied to evaluate the effect of the free carriers or drug loaded carriers, as well 
as that of the non-loaded indometacin on cell survival by measuring the uptake and reduction of 
tetrazolium salt  to an insoluble formazan dye by mitochondrial  succinate  dehydrogenase in 
viable cells. One hundred microliter aliquotes of exponentially growing suspension cultures (1 
x 105 cells) was seeded into 96-well plates, whereas for each treatment group a set of 6 wells 
was used. The cells were incubated overnight and were exposed either to the free carriers, to 
free  indometacin  or  indometacin  loaded  samples  and  incubated  at  310  K  for  72  h.  The 
carrier/culture medium suspensions contained the same drug concentrations as free indometacin 
(12.5–200 µg/ml). Non treated cells were used as control. After the exposure period 100 µl of 
MTT (1 mg/ml) solution was added into each well and the plates were incubated at 310 K for 4 
h to allow MTT-formazan formation. Then formazan crystals were solubilized through addition 
of 110 µl HCOOH (5%) acidified 2-propanol. Finally, absorption at 570 nm was measured with 
a Labexim LMR-1 Microplate Reader 3550 (Bio-Rad, USA).
The  cell  viability  was  calculated  by the  following  formula:  cell  viability  (%)  =  optical 
density (OD) of the treated cells/OD of the non-treated cells x 100.
All  data  were  arranged  as  mean  ±  standard  deviation.  Significant  differences  were 
determined by t-test. P < 0.05 was considered to be significant.
3. Results and discussion
In this study mesoporous silica nanoparticles with improved drug loading properties were 
developed, exploiting the electrostatic interaction between amino-functionalized silica carrier 
and indometacin containing carboxyl functional groups. Taking into account that one of the 
main problems of these systems is the initial burst release of the drug, post-coating of the drug 
loaded mesoporous silica nanoparticles with carbopol was applied. Carbopol was selected as a 
coating  polymer  presuming that  for  in  vivo studies  the  bioadhesion  of  the carbopol-coated 
mesoporous silica nanoparticles will be prerequisite for an improved oral bioavailability of the 
loaded drug.
3.1. Physico-chemical characterization of the mesoporous materials
XRD  data  of  the  MCM-41  samples  with  the  intense  (100)  and  higher  Miller  indices 
reflections in the low 2 theta region confirmed the preservation of the hexagonal structure upon 
aminofunctionalization  and drug loading (Fig.  1).  However,  some broadening and intensity 
decrease  were  observed  for  all  amino-functionalized  mesoporous  samples  (MCM-41NH2, 
MCM-41NH2IND  and  MCM-41NH2INDC)  (Fig.  1).  This  effect  can  be  considered  as 
indication for some structural disorder which occurred during the functionalization procedure. 
Consequently, drug loading and carbopol coating procedure did not influence significantly the 
structural order of mesoporous carrier. 
Also, the presence of crystalline indometacin phase was registered on the initial MCM-41 
and the amino-functionalized MCM-41NH2 samples. This evidenced that indometacin was not 
only contained in the mesopore channels, but could be found on the outer surface of the small 
spherical particles or in the secondary mesopores, e.g.  in the voids among the particles.  In 
contrast, the coating with carbopol resulted in total disappearance of crystalline indometacin on 
the outer mesoporous surface of both indometacin loaded samples (MCM-41INDC and MCM-
41NH2INDC).  These  data  presumed  the  formation  of  carbopol  coating  layer  around  the 
mesoporous nanoparticles.
Nitrogen  adsorption  and  desorption  isotherms  of  the  parent,  amino-functionalized  and 
indometacin loaded samples are presented in Fig. 2 and the calculated textural parameters are 
presented in Table 1. 
Fig.1. XRD patterns of the parent MCM-41, amino-functionalized MCM-41NH2 materials, and 
their  indometacin  loaded  and  carbopol-coated  derivatives  (MCM-41IND,  MCM-41INDC, 
MCM-41NH2IND and MCM-41NH2INDC).
  
Fig. 2. Nitrogen adsorption/desorption isotherms of the parent, the aminofunctionalized, and 
indometacin loaded materials.
Table 1
Physicochemical properties of the parent (MCM-41), amino modified (MCM-41NH2)
and indometacin loaded MCM-41IND and MCM-41NH2IND samples.
Samples ao a (nm) BET (m2/g) PDb (nm) Pore volume (cm3/g)
MCM-41 4.43 1175 2.7 0.99
MCM-41NH2 4.40 570 2.2 0.47
MCM-41IND  4.34 213 2.7 0.20
MCM-41NH2IND 4.31 20 n.d. n.d.
a Cell parameter (a0 = 2d100(3)1/2).
b Pore diameter and pore volume calculated by BJH method.
The  isotherms  of  the  parent  and  amino  MCM-41  exhibited  a  sharp  increase  at  a  relative 
pressure of p/p0 = 0.2–0.4, which was associated with capillary condensation of nitrogen in the 
channels  and with a narrow pore size distribution (Fig.  2).  The isotherms of the MCM-41 
samples were reversible and did not show any hysteresis loop. The textural parameters of the 
parent MCM-41 sample loaded with indometacin showed significant decrease in the surface 
area, pore diameter, and pore volume, however no total blocking can be observed. Modification 
by APTES also resulted in some decrease of the surface area, pore diameter, and pore volume 
whereas the indometacin loading on MCM-41NH2 led to the total pore filling.
The FT-IR spectra of all the studied mesoporous materials (not shown) are characterized by 
an intensive band at 1090 cm-1 which was due to the asymmetric stretching vibration of silica 
structure (Si–O–Si).  Modification of MCM-41 by APTES resulted in the appearance of the 
band at 1540 cm-1, which was attributed to N–H stretching vibrations of aminopropyl anchored
Fig. 3. ATR–FTIR spectra of amino-functionalized MCM-41NH2 and all indometacin loaded 
and carbopol-coated samples.
on the  surface  of  the mesoporous carrier  (Fig.3)  [3,13].  The FT-IR spectra  of  indometacin 
loaded parent and amino-functionalized samples showed the band at 1463 cm-1 characteristic 
for phenyl bands due to the presence of indometacin molecules in the mesopore system. The 
presence of the band at 1552 cm-1 in the spectra of the aminofunctionalized and carbopol coated 
mesoporous silicas was indicative for the formation of a COO--NH3+ bond between the amino 
groups on the surface of the silica carrier and carboxylic groups from indometacin and carbopol 
(Fig. 3). Similar bond formation has been observed between carboxyl modified silica material 
and drug containing amino group (sulfadiazine) [23].
The  13C CP MAS NMR spectra of MCM-41IND and MCM-41NH2-IND are presented in 
Fig.  4.  The spectrum of  MCM-41NH2IND showed resonance  signals  (42.3  and 21.2  ppm) 
typical for carbonin the functional groups of the silica carrier. A broadening of the resonance 
signals  registered  in  the  spectrum  of  non-functionalized  carrier  (MCM-41IND)  could  be 
explained with  the  formation  of  dimers  of  two indometacin  molecules  by hydrogen  bonds 
between  their  carboxyl  groups  (Fig.5a).  This  effect  is  not  observed  in  the  spectrum  of 
functionalized  carrier  (MCM-41NH2IND)  which  could  be  explained  by  the  predominant 
formation  of  hydrogen  bonds  between  NH2 group  of  the  carrier  and  COOH group  of  the 
indometacin molecule (Fig. 5b). There is no shift of the signal of carbon in carboxylic group of 
indometacin (C19 at 178.7 ppm) in both spectra because of the participation of COOH groups in 
the formation on hydrogen bounds in both cases. Thus, the presence of functional groups of the 
carrier hindered the dimerization of indometacin that further could improve its loading.
Fig.  4. 13C NMR spectra  of  indometacin  loaded  parent  and amino-functionalized  materials 
(MCM-41IND and MCM-41NH2IND).
The amino group,  indometacin and carbopol  content  in the samples  were quantified 
using thermogravimetric method.  The amount of amino groups connected to  the surface of 
MCM-41 support was 2.4 wt.%. These data were in good accordance with former results and 
was  confirmed also by the  ninhydrin  method  [24].  The TG analysis  determined the  actual 
amount of drug in the carriers after correcting the curves by water and aminopropyl content 
(Fig. 6). The parent spherical MCM-41 showed lower adsorption capacity for indometacin (30 
wt.%), in comparison to its aminofunctionalized analogue (39 wt.%). One possible reason was 
that the functionalization of mesoporous carrier results in higher drug loading capacity because 
of stronger interaction between the loaded drug molecule and the surface functional groups 
compared to the silanol groups of the unmodified silica carrier. Another reason for the lower 
indometacin  loading  in  non-functionalized  carrier  could  be  indometacin  dimerization  as 
observed by NMR spectra. The bigger size of the dimers probably additionally hindered their  
incorporation into the pores of  the carrier.  The weight  losses from carbopol  coated MCM-
41INDC and MCM-41NH2INDC were 37.0 and 50.6 wt.%, respectively (Fig. 6).
Fig. 5. Scheme representing hydrogen bonds between (a) two molecules of indometacin and (b) 
carboxyl groups of indometacin and amino groups of the functionalized MCM-41NH2 carrier.
The carbopol content was calculated by correcting the actual weight loss with aminopropyl and 
indometacin  contents.  In  order  to  ensure  correct  deduction  of  indometacin  amount,  the 
concentration of the loaded indometacin was checked by measurement of the eventually loss 
indometacin during the coating procedure. The results showed that the loading of indometacin 
after  coating  was  the  same as  it  was  in  non-coated  samples,  suggesting  that  there  was  no 
indometacin diffusion out of the particles during the coating procedure. This fact was probably 
due to the high viscosity of the coating solution as well as the location of indometacin deeply in 
the pores. Thus, the content of carbopol in the coated samples was 7.0 and 11.6 wt.% for MCM-
41INDC and MCM-41NH2-INDC, respectively.  The higher  amount  of  carbopol  detected  in 
MCM-41NH2INDC was due to  the stronger  interaction between the functionalized external 
surface of the mesoporous carrier and the carbopol polymer.
TEM images of the parent and amino modified MCM-41 samples showed the formation of 
spherical particles with a size in the range of 100–400 nm (not shown). The size and the shape 
of drug loaded carbopol-coated particles are presented in  Fig. 7. Particle size determination 
showed that indometacin loading and carbopol coating did not change neither the size of the 
MCM-41 and MCM-41NH2 materials nor the shape of the silica particles.
Fig. 6.  TG curves of the indometacin loaded parent and the amino-functionalized materials 
(MCM-41IND and MCM-41NH2IND), and their  carbopol coated analogues (MCM-41INDC 
and MCM-41NH2INDC).
Fig. 7. Particle size distribution and TEM images of carbopol-coated MCM-41INDC and 
MCM-41NH2INDC samples.
3.2. Drug delivery
The in vitro release process from both non-coated types of nanoparticles (MCM-41IND and 
MCM-41NH2IND) was investigated in two media, simulated gastric fluid with pH of 1.2 and 
simulated intestinal fluid with pH of 6.8. Slower drug release from both types of materials was 
observed in the simulated gastric fluid (Fig. 8). Within the first three hours approximately 15% 
and 28% of indometacin was released in acidic medium whereas the released indometacin in 
slightly alkaline medium was 80% and 99% from amino modified MCM-41NH2 and parent 
MCM-41 particles, respectively. The faster drug release in alkaline medium could be explained 
by two reasons. First, the deprotonation of the silanol groups in alkaline medium and a further  
repulsion between equally charged groups of carrier and indometacin was considered.
Consequently,  the  electrostatic  repulsion  promoted  faster  indometacin  release  out  from the 
mesoporous nanoparticles.  These  results  are  in  agreement  with  the study reporting in  vitro 
release  of  sulfasalazine  from  trymethylammonium  functionalized  silica  nanoparticles  [25]. 
Second, the solubility of indometacin at this pH is higher than that at pH = 1.2 because the drug 
is a weak acid (pKa = 4.5). Thus, this fact also promoted the faster release of indometacin in 
simulated intestinal fluid with pH of 6.8. However, independent of both phenomena, the rate of 
indometacin release in acid medium was still high which was undesired due to the damaging 
effect of indometacin on the gastric mucosa.  In this  view, two approaches were considered 
aiming to decrease the high initial indometacin release: the coating of the nanoparticles with 
carbopol and incorporation of indometacin in amino-functionalized carrier. The coating with 
carbopol did not change the release from non-functionalized particles, in particular 25% from 
carbopol coated vs. 28% from non-coated in the first 3 h (Fig. 8). However, the coating of 
amino-functionalized silica particles decreased significantly the release rate. As can be seen, 8% 
of  indometacin  was  released  from carbopol  coated  amino-functionalized  particles  in  acidic 
medium in the first three hours versus 15% released from non-coated ones. These results were 
explained with the more efficient capping of particle pores in the case of functionalized MCM-
41NH2 carrier due to the electrostatic bonds between carboxylic groups of carbopol and the free 
amino groups of the outer surface of the carrier. Hence, it was evidenced that coating of the 
aminofunctionalized silica particles with appropriate polymer decreased the initial indometacin 
release in the gastric fluid that in vivo could prevent the stomach mucosa.
Fig. 8. In vitro release of indometacin from amino-functionalized non-coated MCM-41NH2IND 
and carbopol coated amino-functionalized MCM-41NH2INDC particles; and parent non-coated 
MCM-41IND and carbopol coated MCM-41INDC particles in simulated gastric (pH = 1.2) and 
simulated intestinal (pH 6.8) fluids.
Another important finding was that independent with or without coating, slower drug release 
was  observed  from  amino-functionalized  nanoparticles  compared  to  non-functionalized. 
Although both types possessed different loading (39% and 30%, respectively), this parameter 
was  not  considered  responsible  for  the  different  release  profiles.  For  example,  the  release 
profiles of functionalized (39% loading) and non-functionalized (30% loading) after 7 h in acid 
buffer became equal, suggesting that the loading had no influence on drug release rate. The 
lower release fromfunctionalized silicas was observed in both media leading to the conclusion 
that the use of amino-functionalized carrier contributed for the sustained indometacin release 
even at increasing pH as it occurred physiologically in gastrointestinal tract. The main factor 
that allowed the sustained release was probably the slow disruption of the electrostatic bonds 
between  the  functional  groups  of  amino-functionalized  carrier  and  indometacin.  One  more 
reason could be the fact that amino-functionalization made particles more hydrophobic that 
delayed the penetration of the release media into the pores. The later additionally hindered the 
drug diffusion out of the pores. Consequently, the sustained release profile of the drug indicated 
that  the  particles  could  be  considered  as  a  platform for  the  development  of  a  once  daily 
administered dosage form.
3.3. Cytotoxicity of the carriers and the drug loaded silica particles
The cytotoxic activity of the carriers and the drug loaded nanoparticles was evaluated in 
two human cell lines after 72 h continuous exposure using the MTT dye-reduction assay. First, 
parent and the amino modified carriers were evaluated for eventual cytotoxic effect. The results  
showed  that  both  placebo  carrier  suspensions  were  practically  devoid  of  cytotoxic  and 
antiproliferative effects in the model cellular populations suggesting their safety (Fig. 9).
The well established ulcerogenic effect of indometacin on gastrointestinal mucosa and the 
related complications constitute a major drawback limiting its clinical usefulness. While it has 
been well  recognized that  much of  the  adverse  effects  are  attributable  to  the  inhibition  of 
prostaglandin  synthesis  [26,27],  new  experimental  data  has  been  gathered  to  support  the 
possible role of additional toxicodynamic mechanisms [28–30]. Non-steroid antiinflammatory 
drugs  like  indometacin,  have  been  documented  to  exert  direct  cytotoxicity  mediated  by 
alteration in cell membrane integrity and functions, induction of free radical formation and lipid
peroxidation, and recruitment of cell death signaling pathways via cyclooxygenase-independent 
mechanisms (28–30). Thus the toxic effects on the gastrointestinal tract tissues, which in case 
of  oral  treatment  are  exposed  to  high  initial  levels  of  indometacin  are  mediated  by  both 
decreased  levels  of  gastroprotective  prostaglandins  and  direct  noxious  effects  on  gastric 
mucosal cells. Thus, the incorporation of indometacin into the mesoporous nanoparticles would 
be beneficial not only for pharmacokinetic point of view, but also could contribute to decreased 
exposure of the non-target gastrointestinal tissues to the noxious activity of indometacin. On 
these  ground  a  comparative  assessment  of  the  cytotoxic  effects  of  free  indometacin  vs. 
indometacin loaded in the nanoparticles was performed (Fig. 10). The free indometacin showed 
superior higher cytotoxicity than drug-loaded mesoporous materials as evident from the cell 
survival data.
Fig. 9. In vitro cytotoxicity of MCM-41 and MCM-41NH2 on K-562 and HL-60 cell lines.
Fig. 10. In vitro cytotoxicity of indometacin loaded MCM-41IND, MCM-41NH2IND and their 
carbopol-coated analogues (MCM-41INDC and MCM-41NH2INDC) on K-562 and HL-60 cell 
lines.
The increase of the indometacin concentration increased cytotoxicity of almost all the samples 
except  for  carbopol  coated  amino-unctionalized  ones.  These  particles  showed  lower 
cytotoxicity even at the highest concentration that correlated well with the slower indometacin 
release from the carbopol-coated particles (Fig. 8).
Thus, the modified release from the carriers was characterized by significant amelioration of 
intrinsic cytotoxicity of indomethacin. These findings indicate that such carriers would greatly 
decrease the propensity of the drug to interact with nonpharmacological targets, and hence an 
improvement  of  its  safety  profile  could  be  expected.  Moreover,  the  mesoporous  systems 
themselves proved to be fully devoid of cytotoxic potential which is of paramount importance 
for their potential utility as pharmaceutical excipients.
4. Conclusion
Nanosized  spherical  mesoporous  MCM-41  particles  were  prepared  and  modified  by 
aminopropyl  groups.  Amino-functionalization of mesoporous MCM-41 carrier  led to  higher 
degree of indometacin loading, in particular approximately 390 mg/g compared to 300 mg/g in 
non-functionalized MCM-41. The coating of amino-functionalized and drug loaded MCM-41 
particles with carbopol significantly decreased the initial burst release of indometacin that could 
prevent  the  damage of  gastrointestinal  mucosa  after  oral  administration.  Another  important 
advantage  of  the  carbopol  coating  is  the  significantly  lower  cytotoxicity  of  the  coated 
indometacin loaded particles compared with the free indometacin.
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